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19 Abstract20 Microbial parasites adapted to thrive at mammalian mucosal surfaces have 21 evolved multiple times from phylogenetically distant lineages into various 22 extracellular and intracellular life styles. Their symbiotic relationships can 23 range from commensalism to parasitism and more recently some host-24 parasites interactions are thought to have evolved into mutualistic 25 associations too. It is increasingly appreciated that this diversity of symbiotic 26 outcomes is the product of a complex network of parasites-microbiota-host 27 interactions. Refinement and broader use of DNA based detection techniques 28 are providing increasing evidence of how common some mucosal microbial 29 parasites are and their host range, with some species being able to swap 30 hosts, including from farm and pet animals to humans. A selection of 31 examples will illustrate the zoonotic potential for a number of microbial 32 parasites and how some species can be either disruptive or beneficial nodes 33 in the complex networks of host-microbe interactions disrupting or maintaining 34 mucosal homeostasis. It will be argued that mucosal microbial parasitic 35 diversity will represent an important resource to help us dissect through 36 comparative studies the role of host-microbe interactions in both human 37 health and disease. 3839 Key words: mucosa, microbiota, bacteria, viruses, innate and adaptive 40 immune responses, parasitic protozoa, parasitic protists, extracellular and 41 intracellular parasites, pathobionts.





42 Introduction43 Intimately associated with the human mucosa functions and defences are the 44 complex microbial communities, called the microbiota, which are increasingly 45 understood to play key roles in myriads of aspects in human health and 46 disease  (Belkaid & Hand, 2014; Clemente et al., 2012). Millions of years of 47 refinements have ensured that mammalian mucosa in a state of homeostasis 48 are effective at mediating simultaneously two conflicting and essential 49 functions: (i) facilitate exchanges between the outside and the inside of the 50 body to allow optimal breathing, nutrient and water uptake and reproduction 51 and (ii) mediate protection against physical, chemical and biological insults, 52 with the latter being mainly microbial in nature. Many of the molecules of the 53 mucosal innate defence system are key for mediating interactions with 54 microbes, including receptors sensing microbes and the central components 55 of mucus (mucins and antimicrobial peptides) can be traced back to early 56 phases of metazoans evolution (Bakshani et al., 2018; Schroder & Bosch, 57 2016). In contrast, some of the effector molecules and cells characteristic of 58 the human adaptive mucosal immune system represent more recent additions 59 to the mucosal armoury against microbes with secretory IgAs (SIgAs), the 60 archetypal antibody in human mucosal secretions, being only shared with 61 reptiles and birds (Smith et al., 2013). The mucosal microbiota form 62 extraordinarily complex microbial ecosystems where bacteria, archaea, 63 microbial eukaryotes and viruses form intricate network of microbe-microbe 64 and host-microbe interactions that can be broadly defined as eubiotic, 65 associated with health, or dysbiotic, associated with disease (Levy et al., 66 2017; Petersen & Round, 2014)(Fig. 1). Eubiotic relationships at mucosal 





67 surfaces are dependent on the functional characteristics of the microbiota 68 community and corresponding finely tuned mucosal innate and adaptive 69 immune responses to microbes, that together are required for harmonious, 70 highly dynamic and continuous host-microbes interactions at mucosal 71 surfaces (Belkaid & Hand, 2014; Clemente et al., 2012; Levy et al., 2017). 72 Finely choreographed host-microbiota interactions are essential to maintain 73 mucosal homeostasis in the broadest possible range of conditions 74 experienced by humans, including variations in diet, exposures to various 75 environmental microbes including pathogens and an increasing range of 76 xenobiotics (Ferreiro et al., 2018; Levy et al., 2017). 77 Mucosal microbial parasites (also referred to as parasitic protozoa or 78 parasitic protists) are phylogenetically highly diverse and heterogenous that 79 can be broadly distributed across human populations and can contribute to 80 important pathologies but that are also often associated with asymptomatic 81 interactions (Chabe et al., 2017; Lukes et al., 2015). Thus human-microbial 82 parasite symbiotic relationships can range from commensalism to parasitism 83 and more recently some host-parasites interactions are suggested to have 84 evolved into mutualistic associations too (Chabe et al., 2017; Loke & Lim, 85 2016; Lukes et al., 2015; Stensvold, 2019). Hence these mucosa residents 86 will be referred to here as “microbial eukaryote symbionts” to better capture 87 the diversity of symbiotic interactions mediated by organisms historically 88 typically referred to as parasites (Lukes et al., 2015; Stensvold, 2019). 89 Notably it is increasingly appreciated that this diversity of symbiotic outcomes 90 is the product of parasites-microbiota-host complex network of interactions 91 (Burgess et al., 2017; Clemente et al., 2012; Rowan-Nash et al., 2019), 





92 further highlighting the importance of contextuality for the phenotypic outcome 93 of human-microbe interactions (Belkaid & Hand, 2014; Clemente et al., 2012; 94 Levy et al., 2017). In this editorial a selection of examples will illustrate how 95 mucosal microbial parasites/symbionts (MMPS) can represent disruptive 96 nodes of the host-microbes complex network of interactions underlying 97 mucosal homeostasis and thus contribute to directly or indirectly to mucosal 98 dysbiosis. In contrast, other examples will illustrate the potential of microbial 99 eukaryote symbionts to contribute to eubiosis (Stensvold & van der Giezen, 100 2018). With these seemingly contradictory considerations in mind, it will be 101 argued that MMPS diversity will represent an important resource to help 102 researchers to dissect the potential causal link between eubiosis and health 103 and dysbiosis and disease through comparative studies. This is a research 104 topic not without controversies and important difficulties and that will require a 105 dramatic increase in the physiological functional characterisation of members 106 of the mucosal microbial communities (Hooks & O'Malley, 2017) including 107 microbial eukaryotes (Chabe et al., 2017; Stensvold & van der Giezen, 2018). 108 Several papers associated with this Special Issue are derived from 109 talks that were delivered at the EMBO Conference “Anaerobic protists: 110 Integrating parasitology with mucosal microbiota and immunology” 111 (http://meetings.embo.org/event/17-anaerobic-protists)(Dessi et al., 2019; 112 Labruyere et al., 2017; Leitsch, 2017; Miranda-Ozuna et al., 2019; Stensvold, 113 2019). These are complemented by articles providing broader perspectives on 114 the study of the MMPS (Bartley et al., 2018; Chihi et al., 2019; Deere et al., 115 2018; Rush et al., 2019; van Gestel et al., 2018; Vargas Rigo et al., 2018). For 116 more in depth coverage of MMPS biology including broader taxonomic 





117 coverage (e.g. Fungi and Helminths), mucosal sites and biology (e.g. lungs, 118 mucus) and topics including parasite genomics, parasite diagnostics and 119 mucosal vaccine, the reader is directed to the following reviews or original 120 papers (Baker et al., 2017; Collins & Belkaid, 2018; Corfield, 2018; Hupalo et 121 al., 2015; Lemieux et al., 2017; Rowan-Nash et al., 2019; Ryan et al., 2017; 122 Serradell et al., 2016).123124 Mucosal microbial eukaryote diversity, host range and zoonoses125 What range of microbial eukaryote symbionts can thrive at our different 126 mucosa, how broadly are they distributed across human populations and what 127 are their host range beyond humans, how genetic diverse are they, what 128 species/genetic lineage are associated with disease and how do these 129 influence the mucosal microbiota and vice versa? These are some of the most 130 basic questions for which we still have relatively limited knowledge for most 131 species. This important knowledge gap currently limits us to properly assess 132 the role in health and disease of microbial eukaryote symbionts and reflects 133 the difficulty of studying mucosal associated organisms and viruses more 134 generally through reductive approaches. A few examples will illustrate the 135 importance of new perspectives one can gain from working on answering 136 these basic questions in humans and animal models. New diagnostic 137 technologies (Ryan et al., 2017) and the increasing number of microbial 138 eukaryote symbionts genome sequence data (Hupalo et al., 2015) are all 139 contributing at providing a better picture of the natural history of MMPS, 140 including non-pathogenic species (Chihi et al., 2019). These in combination 141 with metagenomics surveys (Lokmer et al., 2019) will generate more 





142 comprehensive knowledge on MMPS diversity and host range and their link 143 with health and disease.144 The relatively common gut MMPS Blastocystis spp., Dientemoeba 145 fragilis are reviewed by Stensvold (2019)(both species) and van Gestel et al., 146 (2019)(D. fragilis). These species are thought to be common in some 147 populations but there are a number of contradictory datasets in relation to 148 their potential role in both disease and health and issues with the apparent 149 important prevalence variations between populations (van Gestel et al., 2018). 150 Although potentially misleading detection tools can explain some variation 151 between studies (Gough et al., 2019; van Gestel et al., 2018), a combination 152 of environmental and biological explanations are also likely to play a role. An 153 intriguing possibility suggested for D. fragilis higher prevalence in some 154 countries is pig farming, which could potentially play a role in its higher 155 prevalence in Denmark and the Netherlands where both humans and pigs 156 cohabit in relatively higher densities (van Gestel et al., 2018). This highlights 157 the importance of considering both human and animal prevalence and study 158 in detail the genetic diversity and phylogeny of the microbial eukaryote 159 symbionts to establish their origins among humans and their potential 160 association with animal reservoirs. This is also relevant for the relatively better 161 known species such as Giardia, including in developed countries such as the 162 UK (Horton et al., 2019). A recent survey for Giardia duodenalis among cattle 163 in Scotland further illustrates the importance of studying animal populations, 164 where this species was shown to be common across surveyed beef and dairy 165 cattle (~32%) and included genetic lineages associated with human 166 symptomatic infections (Bartley et al., 2018). In another example, vaccination 





167 to protect dogs and cats from Giardia duodenalis infections (100% 168 prevalence) in a peri-urban disadvantaged community in Argentina, using an 169 elegant vaccination strategy (Rivero et al., 2010), was shown to reduce dog 170 and cat infections with the concomitant reduction of children infections in the 171 community associated with the vaccinated pets (Serradell et al., 2016). This 172 example illustrates the importance of both the knowledge of the epidemiology 173 of a potential pathogen and the molecular mechanisms underlying surface 174 antigen variation to develop an effective vaccine for relevant hosts to 175 eventually also control infections among humans. Similarly, the prevalence of 176 Entamoeba spp., including Entamoeba histolytica, among humans, 177 chimpanzees and baboon in the Greater Gombe Ecosystem in Tanzania, 178 where the human and nonhuman primate populations overlap, demonstrated 179 a high level of prevalence (~60% for all Entamoeba spp. and ~10% of E. 180 histolytica) among all three species highlighting the potential for zoonotic 181 transmission of Entamoeba species (Deere et al., 2018). Notably the 182 presence of E. histolytica in chimpanzees was apparently never associated 183 with symptoms in the tested population, in contrast to human infections 184 (Deere et al., 2018). 185 Beyond the gut, an interesting set of data for Trichomonas vaginalis 186 and Trichomonas tenax, infecting respectively the urogenital tract (Hirt & 187 Sherrard, 2015) and oral cavities (Marty et al., 2017) also highlight the 188 importance of specific and sensitive diagnostics and the knowledge of their 189 distributions beyond humans (Maritz et al., 2014). Through carefully testing 190 the specificity of a molecular diagnostic tool used for T. vaginalis it was 191 discovered that some infections of the urogenital tract (three male urine 





192 samples) could be due to T. tenax rather than T. vaginalis (Brosh-Nissimov et 193 al., 2019). A screening across dogs and cats for oral trichomonads also 194 indicated a potential zoonotic source for T. tenax from pets (Kellerova & 195 Tachezy, 2017). Genotyping T. tenax clinical isolates from humans also 196 established that a subset of genetic lineages are significantly associated with 197 periodontal patients, in addition of being common among the tested 198 population in an affluent setting (35% among patients with periodontitis and 199 19% among healthy controls in the studied French cohort)(Benabdelkader et 200 al., 2019). Notably both T. vaginalis and T. tenax are likely derived from 201 species infecting birds (Maritz et al., 2014) as these two species are 202 respectively more closely related phylogenetically to distinct set of species 203 infecting birds including Trichomonas gallinae, common among pigeons, and 204 Trichomonas gypaetinii isolated from vultures among other Trichomonas spp. 205 isolated from various bird species (Martinez-Diaz et al., 2015). Transfer of T. 206 gallinae from columbiform to passerines has led to important mortality rates 207 for some passerine species dramatically illustrating the potential for a 208 Trichomonas species to jump host and spread rapidly through populations 209 and to become a virulent parasite in some contexts (wild finches such as the 210 common chaffinch) whereas it is often a commensal in others (the 211 columbiform rock pigeon)(Amin et al., 2014). The comparative study of the 212 molecular basis of the interactions between these various Trichomonas 213 species and mucosal landmarks required to initiate and sustain the 214 colonisation of various hosts and mucosa will be of great interest and 215 represent a fascinating model system to study MMPS transfers between birds 216 and from birds to mammals, including humans (Maritz et al., 2014).





217218 Symbiosis: from parasitism to commensalism to mutualism219 Although a number of MMPS are known to be associated with pathologies, 220 leading to important morbidities and mortality rates in some contexts (Bar et 221 al., 2015; Burgess et al., 2017), many infections by the same species are 222 asymptomatic (Chabe et al., 2017; Lukes et al., 2015; Stensvold, 2019). The 223 outcome of host-microbial eukaryote symbionts interactions are dependent on 224 the combination of the characteristics of the host, the microbial eukaryote and 225 the mucosa microbiota, with increasing evidence for an important role played 226 by cross kingdoms interactions (Fig. 1)(Burgess et al., 2017; Rowan-Nash et 227 al., 2019). Inter-kingdom interactions can modulate the inflammatory tone of 228 the mucosa through multiple possible direct and indirect interactions between 229 mucosal microbes, microbes and epithelial cells and microbes and 230 immunocytes (Fig. 2). Notably the epithelial cells play key roles in both 231 sensing microbes and orchestrating the mucosal immunological innate and 232 adaptive responses mediated by the combination of epithelial cells and 233 immunocytes (Fig. 2)(Levy et al., 2017; Petersen & Round, 2014). Primary 234 immunodeficiencies, due to specific genetic background interfering with 235 epithelial cells and/or immunocytes-microbes interactions, or secondary 236 immunodeficiencies due to infections (e.g. HIV/AIDS) or malnutrition, can 237 dramatically increase the susceptibility of the host to numerous infections 238 including by those of MMPS. This is particularly marked for intracellular 239 parasites such as Cryptosporidium and Microsporidia, with the HIV/AIDS 240 pandemic highlighting both the importance of the adaptive immune response 241 in controlling these parasites and the high level of human exposure to these 





242 opportunistic intracellular pathogens from divers zoonotic reservoirs (Khan et 243 al., 2018; Stentiford et al., 2016).244 In other contexts, MMPS could provide benefit to their mammalian 245 carrier. Mice carrying the recently described gut trichomonad Tritrichomonas 246 musculis were shown to be more resistant to challenges by the bacterial 247 pathogen Salmonella typhimurium through enhancing mucosal defences by 248 increasing intestinal inflammation via inflammosome activation and increase 249 of the proinflammatory IL-18 production leading to a TH1/TH17 immune 250 response (Chudnovskiy et al., 2016). This higher protection level to 251 Salmonella was howeve  associated with a cost as T. musculis colonisation 252 was also associated with higher rate of colorectal cancer (Chudnovskiy et al., 253 2016). This contrasts with helminths infections that tend to inhibit gut 254 inflammation through stimulating TH2/Treg responses (Cortes et al., 2018). 255 These contrasting examples illustrate the importance, and potential 256 great value, of increasing our knowledge of the natural history of mammal-257 MMPS interactions and the importance of studying various microbial 258 eukaryote symbiont species in humans and animal models to dissect the 259 complex host-MMPS-mirobiota interactions to illuminate their influence in both 260 health and disease (Loke & Lim, 2016). Additional examples of potentially 261 beneficial microbial eukaryote symbionts; including Entamoeba spp. and 262 Blastocystis are discussed in this Special Issue (Stensvold, 2019) and in other 263 contexts (Chabe et al., 2017; Lukes et al., 2015; Stensvold & van der Giezen, 264 2018) and in the next section. 265266 Microbial eukaryote symbionts/parasite-bacteria-virus interactions





267 The complex interplay between MMPS, bacteria, archaea and viruses and 268 mammalian host health and disease status is increasingly being uncovered 269 through the study of various microbial cellular species, bacteriophages and 270 eukaryote infecting viruses, different mucosal surfaces and mammalian 271 species, including humans (Burgess et al., 2017; Chabe et al., 2017; 272 Clemente et al., 2012; Rowan-Nash et al., 2019). Here a few examples 273 illustrating the link between these interactions and health and disease are 274 covered with MMPS potentially contributing to either eubiosis or dysbiosis 275 depending on context of the hosts and their associated microbiota and 276 environmental factors such as diet and xenobiotics (e.g. antibiotics) (Fig. 3).277 Arguably one of the most fascinating and complex example includes 278 Trichomonas vaginalis that infect the urogenital tracts (UGT) of humans (Hirt 279 & Sherrard, 2015). A complex set of interactions between T. vaginalis, RNA 280 viruses infecting T. vaginalis (TVV), the bacteria Mycoplasma hominis forming 281 symbiosis with T. vaginalis and other bacteria associated with bacterial 282 vaginosis, are all thought to contribute in concert to symptomatic infections, 283 adverse pregnancy outcomes and increase transmission and acquisition of 284 human infecting viruses, including HIV, HPV and HSV-2 (Hirt & Sherrard, 285 2015; Kissinger, 2015). This is thought to be mediated through several 286 mechanisms including, boosting the inflammatory tone of the UGT, increasing 287 the population of target immunocytes for HIV and induction of microlesions 288 disrupting the mucosal barrier (Kissinger, 2015). Furthermore, although 289 human viruses including HIV and HSV are not known to infect T. vaginalis, 290 HIV and HSV viral particles can be internalised by the parasite and potentially 291 be transferred to, and infect, human cells in a new host (Pindak et al., 1989; 





292 Rendon-Maldonado et al., 2003). Although T. vaginalis can induce tissue 293 damage and inflammation on its own, TVV and Mycoplasma hominis can act 294 synergistically to dramatically boost inflammations associated with T. vaginalis 295 infections as reviewed by Dessi and colleagues (Dessi et al., 2019). Dysbiosis 296 associated with infections by T. vaginalis is also thought to contribute to the 297 pathobiology of T. vaginalis (Fichorova et al., 2017; Mercer & Johnson, 2018). 298 Direct targeting of bacteria peptidoglycans by the parasite through enzymes of 299 bacterial origins (Pinheiro et al., 2018) could potentially contribute to modulate 300 the microbiota bacterial taxonomic composition in addition to contributing to T. 301 vaginalis capacity to colonise the mucosal surface. The combination of the 302 parasite and several bacterial species characteristic of dysbiotic vaginal 303 microbiota associated with trichomoniasis, were also recently shown to 304 synergistically affect the integrity of the tight junction complex of the 305 cervicovaginal epithelial cells (Hinderfeld et al., 2019). Notably, treating T. 306 vaginalis infections with metronidazole can liberate from the killed parasite 307 TVV particles and/or Mycoplasma hominis cells leading to the boosting of 308 inflammation and to infection of human cells by M. hominis (Dessi et al., 2019; 309 Thi Trung Thu et al., 2018). These different aspects associated with T. 310 vaginalis infections illustrates the intricate associations of the parasite with 311 bacterial (Mycoplasma) and viral (TVV) endosymbionts, the bacterial 312 members of the UGT microbiota and how these interactions can influence the 313 parasite pathobiology including increasing human infecting virus transmission 314 rates. These considerations will be important to complement more traditional 315 investigations focusing on the study of specific aspects of host-parasite 316 interactions, such as the potential role of environmental glucose concentration 





317 variation (Miranda-Ozuna et al., 2019) and cell surface and secreted factors 318 such as exosomes (Mercer & Johnson, 2018), in modulating the virulence of 319 the parasite. These examples illustrate dramatically the importance to 320 investigate host-MMPS-microbiota-virus interactions in an integrative manner 321 to develop more refined diagnostics and novel prophylactic and therapeutic 322 strategies to eventually promote reproductive and sexual health more 323 efficiently. It will also be of interest to investigate the possibility that related 324 endosymbionts (to TVV and Mycoplasma) are also present in other 325 Trichomonas species including bird infecting species and T. tenax associated 326 with periodontitis (described in the previous section).327 The MMPS Giardia, Entamoeba and Cryptosporidium are also known 328 to be infected by RNA viruses (Gomez-Arreaza et al., 2017). Cryptosporidium 329 infected virus are associated with higher rate of the parasite propagation 330 capacity; however, it is not clear if this increases the virulence of such 331 infections. Similarly there is currently no evidence for Giardia and Entamoeba 332 that their RNA viruses can contribute to boosting the pathobiology of these 333 parasites (Gomez-Arreaza et al., 2017). Complex interplay between Giardia, 334 Entamoeba and Cryptosporidium with bacteria members of the microbiota 335 have also been shown to influence the virulence of these parasites in both 336 negative (e.g. inhibiting infections) or positive ways (e.g. promoting 337 virulence)(Burgess et al., 2017; Rowan-Nash et al., 2019). A remarkable 338 example illustrating the importance of the microbiota in playing a role in 339 reducing the impact of Cryptosporidium infection was uncovered when 340 investigating two candidate drugs to treat the parasite. Two novel drugs that 341 had promising properties in initial in vitro tests had opposite effect on 





342 Cryptosporidium infections in a mouse model (Gorla et al., 2014). Although 343 one of the drugs was potent in controlling the parasite, the other drug was 344 shown to actually boost infection levels, which was associated with a 345 significant change in the bacterial taxonomic composition of the gut 346 microbiota, with in particular a dramatic increase of the population of the 347 mucin loving gut bacteria Akkermansia muciniphila (2,800-fold increase 348 compared to the pre-treatment state), suggesting a dysbiotic microbiota 349 (Gorla et al., 2014). This was rationalised as an off-target impact of the drug 350 on members of the gut microbiota. Although A. muciniphila is considered to be 351 an important mutualist associated with human health (Cani & de Vos, 2017), 352 the significant boost in Cryptosporidium infection level could be explained by 353 an excessive degradation by A. muciniphila of the mucus protective layer in 354 the gut facilitating access to, and eventual infection of, epithelial cells by 355 Cryptosporidium. An apparently similar outcome was observed in a mouse 356 model with a humanised gut microbiota fed with a diet depleted from plant 357 fibbers, which led to the depletion of the mucus protective layers by the 358 microbiota and higher susceptibility to pathogens (Desai et al., 2016). These 359 examples illustrate how environmental factors, including xenobiotics (an 360 antibiotic in the example above) and diet, can influence the mucosal microbial 361 ecology and by doing so modulate the host susceptible to infections by 362 potential pathogens, including MMPS.363364 Antibiotics and vaccines for mucosal parasites/symbionts365 In contrast to the availability of a broad range of antibiotic treatment regiments 366 for bacteria, there are far less efficient options to treat with drugs symptomatic 





367 infections due to microbial parasites (Farthing, 2006; Leitsch, 2017). As for 368 bacteria, there is also the issue of microbial parasites developing resistance to 369 existing drugs regiments and for off-target effects on the microbiota (Wypych 370 & Marsland, 2018). Furthermore some patients can develop strong reactions 371 to some drugs including to the commonly used metronidazole targeting 372 anaerobic parasites (Leitsch, 2017). These considerations stimulate 373 continuous research efforts to identify new drugs to treat microbial parasites, 374 either based on modifying existing well established drugs such as 5-375 nitroimidazole (Leitsch, 2017), or new drugs such as plant derived 376 phenanthrenes (Vargas Rigo et al., 2018). Irrespective of the drug, it is 377 increasingly appreciated necessary to consider their broad impact on the host 378 microbiota, with increasing evidence that antibiotic treatments are being 379 associated with dysbiosis favouring opportunistic pathogens, including 380 pathobionts, and/or leading to a difunctional immune response to microbial 381 and other antigens that can lead to debilitating conditions such as allergies 382 and asthma (Wypych & Marsland, 2018). In the case of the treatment of 383 anaerobic mucosal parasites (such as Trichomonas and Giardia) with 384 metronidazole/imidazole the anaerobic members of the microbiota will also be 385 affected (Leitsch, 2017). This can contribute to dysbiosis in the gut microbiota 386 in particular where anaerobes are known to play important roles (Wypych & 387 Marsland, 2018)(Fig. 3).388 In comparison to drug treatments options, vaccines for MMPS are even 389 less well developed. This is due to the combination of the inherent difficulties 390 in developing effective mucosal vaccines (Lycke, 2012) and the complex 391 biology of MMPS, including their capacity to mediate cell surface antigen 





392 variation (Deitsch et al., 2009; Gargantini et al., 2016) and the little knowledge 393 we have on the nature of the host immune response to eradicate MMPS 394 (Chapwanya et al., 2016; Farthing, 2006). One promising strategy that takes 395 advantage of the properties of VSP proteins from Giardia (Gargantini et al., 396 2016) and viral-like particles has great potential to develop novel oral 397 vaccines for various pathogens (Serradell et al., 2019), including a broad 398 range of MMPS in addition to Giardia (Serradell et al., 2016).399400 Conclusion and some speculations401 From the examples covered here and in cited publications one can conclude 402 that it might be more appropriate to refer to many extracellular microbial 403 eukaryotic symbionts with various pathogenic potential as pathobionts that is, 404 they are members of the mucosal microbial ecosystems that can become 405 pathogenic in some contexts where host genetic, environment and properties 406 of the microbial community as a whole all play a role (Chow et al., 2011). 407 Acquired immunodeficiencies or transfer of MMPS between different hosts 408 species can lead to sub-optimal interactions with some species becoming 409 pathogenic (Farthing, 2006; Price et al., 2017). In contrast intracellular 410 parasites, including the Apicomplexa Cryptosporidium and the Microsporidia, 411 are typically thought to be primarily gut pathogens (Farthing, 2006), as they 412 must directly exploit their host cell energy and metabolites to proceed through 413 their life cycle and in the process compromise the integrity of the epithelial 414 monolayer of the gut (Dean et al., 2016; Farthing, 2006). One aim of this 415 editorial was to illustrate specific aspects of the intricate and complex 416 interactions taking place between MMPS, the other members of the 





417 microbiota and their animal or human hosts. These highlight the importance of 418 collaborative research projects integrating parasitology, microbiology, 419 virology, pharmacology and mucosal immunology in the context of both basic 420 and medical and veterinary research on the factors influencing mucosa health 421 and disease. Generating more comprehensive knowledge on the link between 422 these microbial interactions and mucosal and systemic health and disease is 423 undoubtedly one of “the most difficult and challenging scientific endeavour of 424 our time”(Birchenough & Hansson, 2017), as it will need to identify and 425 characterise key aspects of thousands of highly dynamic interactions 426 mediated by a complex cocktail of metabolites, cell-virus and cell-cell 427 interactions involving complex microbial communities, epithelial cells and 428 immunocytes. The knowledge derived from the study of these complex 429 network of interactions will be required to eventually develop much needed 430 novel prophylactic, including mucosal vaccines for overt pathogens, and 431 therapeutic strategies (including highly specific drugs, prebiotics, faecal 432 transplants), to regenerate, maintain and promote human and animal health at 433 mucosal surfaces. It is also suggested that considering microbial eukaryote 434 symbionts/parasites will provide important opportunities for much required 435 comparative studies to delicately dissect key nodes orchestrating mucosal-436 microbes interactions and how these are causally linked to the specific 437 phenotypic outcomes in their human and animal hosts. Contextualisation of 438 the diversity of both MMPS, the microbiota at large (bacteria, archaea and 439 viruses) and their host within an evolutionary and ecological framework will 440 also likely be important at helping building a more predictive theoretical 
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722723 Figure legends724725 Fig. 1. The now generally accepted new paradigm of microbe-microbe / host-726 microbe complex network of interactions that can contribute to health 727 (maintaining homeostasis) or disease (inducing excessive inflammation 728 through time and space) status of the animal/human host. The terms eubiosis 729 and dysbiosis relate to the microbiota functional activities associated with 730 respectively health through maintaining mucosal homeostasis (ensuring 731 optimal mucosal functionality) or pathologies due to excess inflammation 732 leading to damage mucosal surfaces and that can also contribute to disrupt 733 systemic physiology and sub-optimal cognitive capacities. See main text and 734 cited references for the conceptual limitations on the use of eubiosis and 735 dysbiosis. 736737 Fig. 2. The complex network of interactions at mucosal surfaces between 738 microbes, epithelial cells and immunocytes modulating the immunological and 739 inflammatory status of the mucosal surfaces. Optimal interactions ensure 740 adequate responses to the presence of members of the microbiota and robust 741 challenges to pathogens and at the same time tolerance to innocuous 742 antigens required to maintain long term functionality of the mucosal surface 743 underlying optimal digestion and nutrient uptake, breathing, or reproduction. 744 Arrows indicate direct (e.g. physical contact) and indirect (e.g. metabolites or 745 signalling molecules) interactions such as infection of epithelial cells by 746 intracellular pathogens (viruses or Microsporidia, both illustrated) and doted 747 arrows indicate indirect (e.g. though metabolites) interactions between 





748 illustrated cells. Note in particular the central node/role of epithelial cells that 749 integrate, and in effect coordinate/orchestrate the complex network of 750 interactions between microbes and immunocytes. A virus (several green 751 “stars”) infected epithelial cell is illustrated as is a virus infected trichomonad 752 (one green “star”, see example in the text). In addition, some viruses/phages 753 infect bacteria also contributing to the overall functional properties of the 754 mucosa microbial ecology. Intracellular bacteria (black rectangles) and 755 Microsporidia (blue cell and spores) are also illustrated within epithelial cells. 756 ZO, Zonula occludens - tight junction; ECM, extra cellular matrix. For 757 simplicity the presence of mucus and the glycocalyx interacting with luminal 758 microbes are not shown and only a monolayer of epithelial cells (e.g. as in the 759 intestine) is illustrated.760761 Fig. 3. Potential role of MMPS in inducing dysbiosis or eubiosis at mucosal 762 surfaces. In the context of dysbiosis this would contribute to the loss of 763 mucosal homeostasis, and by doing so to a number of potential pathologies 764 that eventually will translate in dysfunctional mucosa leading to disease both 765 locally, e.g. mucosa inflammation, or more distal impacts. The illustrated 766 examples include: Trichomonas vaginalis (Tv) contributing to increasing the 767 vaginal bacterial diversity associated with bacterial vaginosis, a form of pro-768 inflammatory dysbiosis of the urogenital tract (UGT). T. vaginalis infections 769 are also associated with the loss of mutualists in the UGT. Entamoeba 770 histolytica (Eh) can contribute to colitis, mucosa perforation and translocation 771 of both parasites and some member of the gut microbiota into the portal vein 772 and systemic tissues that can contribute to highly damaging systemic and 





773 local inflammations in the digestive tract (DT) and beyond. In contrast, the 774 loss of some microbial eukaryotes, including potentially Blastocystis hominis 775 (Bh) and some Entamoeba spp. (especially, non-histolytica species), could 776 contribute to the gut microbiota reduced bacterial diversity associated with a 777 dysbiotic state. Similarly, metronidazole treatments aiming at eradicating 778 anaerobic mucosal microbial parasites such as Giardia and Trichomonas 779 species, will also contribute at disrupting the mucosal microbiota by killing 780 important bacterial anaerobes and can favour the expansion of bacterial 781 pathobionts in the DT and the respiratory tract (RT). See main text for 782 examples and citations. MMPS can also influence the RT - e.g. (Maritz et al., 783 2014) - but this is not covered here.





Fig. 1. The now generally accepted new paradigm of microbe-microbe / host-microbe complex network of 
interactions that can contribute to health (maintaining homeostasis) or disease (inducing excessive 
inflammation through time and space) status of the animal/human host. The terms eubiosis and dysbiosis 
relate to the microbiota functional activities associated with respectively health through maintaining mucosal 
homeostasis (ensuring optimal mucosal functionality) or pathologies due to excess inflammation leading to 
damage mucosal surfaces and that can also contribute to disrupt systemic physiology and sub-optimal 
cognitive capacities. See main text and cited references for the conceptual limitations on the use of eubiosis 
and dysbiosis. 
254x190mm (300 x 300 DPI) 





Fig. 2. The complex network of interactions at mucosal surfaces between microbes, epithelial cells and 
immunocytes modulating the immunological and inflammatory status of the mucosal surfaces. Optimal 
interactions ensure adequate responses to the presence of members of the microbiota and robust challenges 
to pathogens and at the same time tolerance to innocuous antigens required to maintain long term 
functionality of the mucosal surface underlying optimal digestion and nutrient uptake, breathing, or 
reproduction. Arrows indicate direct (e.g. physical contact) and indirect (e.g. metabolites or signalling 
molecules) interactions such as infection of epithelial cells by intracellular pathogens (viruses or 
Microsporidia, both illustrated) and doted arrows indicate indirect (e.g. though metabolites) interactions 
between illustrated cells. Note in particular the central node/role of epithelial cells that integrate, and in 
effect coordinate/orchestrate the complex network of interactions between microbes and immunocytes. A 
virus (several green “stars”) infected epithelial cell is illustrated as is a virus infected trichomonad (one 
green “star”, see example in the text). In addition, some viruses/phages infect bacteria also contributing to 
the overall functional properties of the mucosa microbial ecology. Intracellular bacteria (black rectangles) 
and Microsporidia (blue cell and spores) are also illustrated within epithelial cells. ZO, Zonula occludens - 
tight junction; ECM, extra cellular matrix. For simplicity the presence of mucus and the glycocalyx 
interacting with luminal microbes are not shown and only a monolayer of epithelial cells (e.g. as in the 
intestine) is illustrated. 
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dysbiosis this would contribute to the loss of mucosal homeostasis, and by doing so to a number of potential 
pathologies that eventually will translate in dysfunctional mucosa leading to disease both locally, e.g. 
mucosa inflammation, or more distal impacts. The illustrated examples include: Trichomonas vaginalis (Tv) 
contributing to increasing the vaginal bacterial diversity associated with bacterial vaginosis, a form of pro-
inflammatory dysbiosis of the urogenital tract (UGT). T. vaginalis infections are also associated with the loss 
of mutualists in the UGT. Entamoeba histolytica (Eh) can contribute to colitis, mucosa perforation and 
translocation of both parasites and some member of the gut microbiota into the portal vein and systemic 
tissues that can contribute to highly damaging systemic and local inflammations in the digestive tract (DT) 
and beyond. In contrast, the loss of some microbial eukaryotes, including potentially Blastocystis hominis 
(Bh) and some Entamoeba spp. (especially, non-histolytica species), could contribute to the gut microbiota 
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